MSTN and Duchenne muscular dystrophy: For most of these trials, functional tests to monitor the progression of DMD in the clinic (i.e., the North Star Ambulatory Assessment) were used as outcome measures to evaluate the efficacy of myostatin inhibition against muscle wasting, and therefore strength decline.